ABSTRACT We studied the influence of the following variables on the time interval from initiation of an intravenous infusion of 750,000 U of streptokinase until reperfusion (reperfusion time) in 140 consecutive patients with an evolving acute myocardial infarction: (1) the rate of infusion of streptokinase, (2) the duration of chest pain before initiation of treatment, (3) patient age, (4) patient sex, (5) location of infarction, (6) history of previous myocardial infarction, and (7) pretreatment pathologic Q waves. The time of reperfusion was recognized by clinical criteria that were completely concordant with the anatomic findings in all 1 19 patients in whom patency or occlusion of the artery of infarction was established at delayed angiography (n = 116) or at postmortem examination (n = 3). The mean reperfusion time for the 129 patients for whom data were available was 49 36 min. The reperfusion time was inversely related to the rate of infusion of streptokinase (r = .41, p < .001), but this effect of infusion rate appeared to plateau at rates of greater than 500 U/kg/min. In the 64 patients receiving infusions at rates of 500 U/kg/min or less, the mean reperfusion time was 60 + 40 min, whereas in the 58 patients receiving the drug at rates greater than 500 U/kg/min it was 35 + 22 min (p < .001). The duration of chest pain before treatment was the only other studied variable found to influence the reperfusion time, but only at infusion rates of less than 250 U/kg/min (r= .6, p < .01). Our findings indicate that in patients with acute myocardial infarction who receive high-dose intravenous streptokinase, the time interval to reperfusion can be minimized by increasing the infusion rate up to at least 500 U/kg/min and by shortening the delay from onset of symptoms to treatment.
improve ventricular function"5 and survival.i' 9 Both experimental' 02 and clinical"3-"' studies indicate that the critical determinant of the extent of myocardial necrosis and salvage is the duration of myocardial ischemia before reperfusion. In clinical practice, this ischemic period comprises (1) the time interval from the onset of infarction to the commencement of treatment, which is predominantly a logistical problem, 1620 and (2)-the time interval from commencement of treatment until reperfusion, which is predominantly a biological variable.
In this study, we investigate the potential effect of the following factors on the time interval from treatment until reperfusion by intravenous streptokinase: (1) the rate of infusion of streptokinase, (2) the duration of chest pain before initiation of treatment, (3) patient age, (4) patient sex, (5) the location of infarction, (6) the presence of eletrocardiographic and/or historical evidence of a previous infarction, and (7) the presence of pretreatment, pathologic Q waves in the region of the current infarction.
Methods
Patient population. The study population consisted of 140 consecutive patients with acute myocardial infarction (107 men, 33 women) who were 62 + 12 years old (range 32 to 86) and were included in a prospective study of intravenous streptokinase. All fulfilled the following criteria: (1) The effect of the rate of infusion of streptokinase on reperfusion time. Figure 1 illustrates that in the 122 patients in whom both the rate of infusion of streptokin- THERAPY AND PREVENTION-THROMBOLYSIS ase and the reperfusion time were available, there was an inverse relationship between the rate of infusion of streptokinase and the time interval to reperfusion (r = .41, p < .001), which was similar for patients with anterior and those with inferior infarction. This relationship appeared to plateau at infusion rates of about 500 U/kg/min. In the 64 patients receiving infusions at rates of 500 U/kg/min or less, the mean reperfusion time was 60 + 40 min compared with 35 + 22 min in the 58 patients who received infusions at rates of greater than 500 U/kg/min (p < .001). Figure 1 also indicates that reperfusion time was less than 50 min in only 45% of the 64 patients who received a slower infusion rate compared with 83% of the 58 patients who received a faster infusion rate (p < .001).
Further analysis of the influence of the rate of streptokinase infusion on the reperfusion time was performed by dividing the study population into five subgroups according to the rate of intravenous infusion (table 1). In 24 patients the infusion rate was 250 U/kg/min or less (very slow group), in 39 patients it was 260 to 500 U/kg/min (slow group), in 20 patients it was 510 to 750 U/kg/min (intermediate group), in 16 patients it was 760 to 1000 U/kg/min (rapid group), and in 23 patients it was greater than 1000 U/kg/min (very rapid group). The difference in the mean reperfusion times between the very slow and slow infusion rate groups (70 ± 49 and 54 ± 34 min, respectively) was not statistically significant (p = .07), but they were both significantly longer (p < .01) than the mean reperfusion times in the intermediate (34 ± 19 min), rapid (38 ± 23 min), and very rapid (34 ± 25 min) infusion rate groups. There was no difference in mean reperfusion time among the latter three groups.
The effect of the duration of chest pain on reperfusion time. For the entire study population, there was no correlation between the duration of chest pain before streptokinase and reperfusion time (r = . 13). To minimize the influence of the infusion rate of streptokinase, the relationship was separately analyzed in five subgroups, each including patients receiving a narrow range of infusion rates defined as the mean value + 15% of each of the subgroups described in table 1. The corresponding infusion rate ranges were 210 ± 30 U/kg/min (17 patients), 370 ± 50 U/kg/min (19 patients), 600 + 90 U/kg/min (17 patients), 880 ± 130 U/kg/min (16 patients), and greater than 1450 U/kg! min (10 patients). Only in the 17 patients from the slowest infusion rate group (180 to 240 U/kg/min) was there a significant correlation (r = .6, p = .005) between the duration of chest pain and the reperfusion time (figure 2). There was no correlation, or even a trend, for any of the subgroups receiving faster infusion rates of streptokinase.
Other clinical variables (table 2) . The reperfusion time was not influenced by any of the other clinical variables that were studied, including patient age, patient sex, location of infarction, the presence of electrocardiographic and/or historical evidence of a previous infarction, and the presence of pathologic Q waves in the region of the current infarction before initiation of streptokinase therapy.
Discussion
The wide range of infusion rates in this study reflects our progressive experience with intravenous streptokinase. Initially, streptokinase was administered very rapidly (in 5 to 15 min) to achieve a high serum concentration similar to that achieved with intracoronary administration; however, these very rapid infusion rates frequently caused hypotension."7 19, 22. 23 Subsequently, a range of slower infusion rate protocols were used in an attempt to prevent the hypotensive effect. Therefore, our total experience provided the data necessary to study the effect of varying infusion rates on reperfusion time.
Our data indicate that in patients with evolving acute myocardial infarction, the reperfusion time is inversely related to the rate of streptokinase infusion and, at slow infusion rates, is also directly related to the duration of chest pain before initiation of treatment.
Since the rate of infusion affects the serum concentration of streptokinase,24 25 our results imply that the rate of thrombolysis is a function of the serum concentration of this drug. This finding is consistent with the known direct relationships between the concentration of streptokinase, the concentration of plasminogen activator complex,6 27 and the rate of thrombolysis.7 28 The effect of the streptokinase infusion rate on the reperfusion time appears to plateau at a rate of about 500 U/kg/min and therefore, faster infusion rates, which are more likely to produce significant hypotension, appear to have no advantage with respect to earlier reperfusion. If one accepts that the chest pain of acute myocardial infarction commences at about the time of thrombotic occlusion of the artery of infarction, then the duration of chest pain in patients with acute infarction is an indirect approximation of age of thrombus, or at least the age of the final occlusive portion of the thrombus. Our finding that at slow infusion rates of streptokinase, the duration of chest pain was a determinant of the reperfusion time, suggests that the age of the thrombus influenced the results of thrombolytic therapy. This is in accordance with clinical studies using streptokinase in which the duration of symptoms before initiation of treatment was shown to be a determinant of both the rate of successful reperfusion'6 [29] [30] [31] and the rapidity of thrombolysis,29 32 and is also consistent with experimental studies showing that older thrombi are more resistant to lysis. 33 34 This age-related resistance of the thrombus to lysis may be due to an increased degree of fibrin cross-linking within the thrombus,> a decrease in plasminogen content of the thrombus due to its retraction27 or thrombus growth with time.7 The finding that the age of the thrombus was a factor only in patients who received streptokinase at slow infusion rates is consistent with the experimental data reported by McDonagh et al. 38 who found the presence of fibrin cross-linking to be a determinant of the rate of thrombolysis at low concentrations of urokinase, but not at high concentrations.
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The considerable scatter of our data suggests that reperfusion time after intravenous streptokinase is probably affected by other factors.9 such as the size of the thrombus independent of its age,40 serum levels of plasminogen, antiplasmins,4) and neutralizing antistreptokinase antibodies,42A4 and especially access of streptokinase to the thrombus.24. 45 46 The latter depends on the surface area of the thrombus exposed to the lytic agent24 and the antegrade and collateral blood flow reaching the occlusive thrombus,46 which may be especially important when the thrombus is situated distal to a tight stenosis.
A potential limitation of this study is that the determination and timing of reperfusion was based on nonangiographic criteria. However. this reperfusion syndrome, consisting of relief of chest pain, resolution of ST segment elevation, and CK washout, has a sound physiologic basis and its validity is supported by (1) experimental studies,479 (2) the complete concordance between the occurrence of this syndrome and the finding of patency of the artery of infarction in our study, and (3) the excellent concordance between these signs and angiographically recognized reperfusion in several intracoronary streptokinase studies.29 5 In the intracoronary studies of Lee, Rentrop, Mathey, and Ganz and their colleagues,9 50 > the clinical signs of reperfusion usually occurred within minutes of the angiographic demonstration of arterial patency and in some studies, these clinical signs were used to indicate when to check the patency of the artery of infarction by angiography.9°08-5' Furthermore, these clinical signs of reperfusion have also been adopted by several other investigators using intravenous streptokinase.'6 19. 59. 60 
CIRCULATION
The delay in the abrupt washout of CK relative to the relief of chest pain and resolution of ST segment elevation in six of our patients was similar to that observed in four patients in our intracoronary streptokinase study.52 In these four patients, the delay in CK washout relative to angiographic patency, as well as relief of chest pain and resolution of ST segment elevation, was associated with initially partial reperfusion and sluggish coronary flow. However, in all four patients, a rapid washout of CK occurred when the flow in the artery of infarction improved and the progression of contrast became similar to that in the other arteries. Although our definition of reperfusion time has some inherent error, it was based on a sampling frequency of electrocardiographic recordings similar to the usual 15 min interval between coronary angiograms used in intracoronary studies. Since our definition was applied consistently throughout our study, this inaccuracy is not likely to have distorted our conclusions that the reperfusion time is affected by the streptokinase infusion rate and by the duration of chest pain before treatment.
Clinical implications. Our data indicate that in patients with acute myocardial infarction who are treated with high-dose intravenous streptokinase, the reperfusion time can be reduced by starting the infusion of streptokinase as soon as possible after the onset of symptoms and infusing streptokinase at a rate of about 500 U/kg/ min, if this dose can be tolerated. Infusion of streptokinase at rates faster than 500 U/kg/min does not appear to be advantageous with respect to reperfusion time.
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